Home / Stocks / JNJ

Johnson & Johnson (JNJ, Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued

Johnson & Johnson (JNJ, Pharmaceuticals) trades at a blended P/E of 23.0, about 42% above its historical normal valuation, with a forward growth estimate of 10.1% and a PEG of 2.27. Analysts' one-year estimates have been hit 91% of the time.

DATA AS OF 2026-08-21
Blended P/E
23.0
Normal P/E
16.2
PEG
2.27
Fwd growth
10.1%
Div yield
2.1%
RSI (14)
61.7
Neutral

The Street vs SeerForecast

Wall Street's mean price target for JNJ is $272.50 across 22 analysts, 0.8% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from trading above fair value (2026-06-03) to significantly overvalued (2026-08-21).

Price and rating by weekClose moved +16.6 percent from 2026-06-03 to 2026-08-17, with 5 rating changes over 21 recorded weeks.2026-06-03: Trading above fair value, close 223.24 (recalculated)2026-06-10: Trading above fair value, close 238.49 (recalculated)2026-06-14: Trading above fair value, close 240.87 (recalculated)2026-06-16: Trading above fair value, close 235.18 (recalculated)2026-06-21: Trading above fair value, close 228.39 (recalculated)2026-07-02: Trading above fair value, close 263.04 (recalculated)2026-07-06: Significantly overvalued, close 259.33 (recalculated)2026-07-09: Significantly overvalued, close 259.10 (recalculated)2026-07-12: Significantly overvalued, close 256.98 (recalculated)2026-07-13: Significantly overvalued, close 257.77 (recalculated)2026-07-14: Significantly overvalued, close 253.85 (recalculated)2026-07-20: Trading above fair value, close 248.82 (recalculated)2026-07-22: Trading above fair value, close 255.63 (recalculated)2026-07-25: Significantly overvalued, close 263.40 (recalculated)2026-07-27: Significantly overvalued, close 265.95 (recalculated)2026-07-31: Trading above fair value, close 256.35 (recalculated)2026-08-03: Trading above fair value, close 256.352026-08-07: Trading above fair value, close 259.24 (recalculated)2026-08-10: Significantly overvalued, close 259.242026-08-14: Significantly overvalued, close 260.35 (recalculated)2026-08-17: Significantly overvalued, close 260.352232602026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 20.8+28%Trading above fair value
2026-06-10P/E 20.9+29%Trading above fair value
2026-06-14P/E 20.9+29%Trading above fair value
2026-06-16P/E 20.9+29%Trading above fair value
2026-06-21P/E 20.9+29%Trading above fair value
2026-07-02P/E 22.7+40%Trading above fair value
2026-07-06P/E 23.5+45%Significantly overvalued
2026-07-09P/E 23.5+45%Significantly overvalued
2026-07-12P/E 23.0+41%Significantly overvalued
2026-07-13P/E 23.0+41%Significantly overvalued
2026-07-14P/E 23.0+41%Significantly overvalued
2026-07-20P/E 22.5+38%Trading above fair value
2026-07-22P/E 22.5+38%Trading above fair value
2026-07-25P/E 23.3+44%Significantly overvalued
2026-07-27P/E 23.3+44%Significantly overvalued
2026-07-31P/E 22.6+39%Trading above fair value
2026-08-03P/E 22.7+40%Trading above fair value
2026-08-07P/E 22.7+40%Trading above fair value
2026-08-10P/E 22.9+41%Significantly overvalued
2026-08-14P/E 23.1+43%Significantly overvalued
2026-08-17P/E 23.0+42%Significantly overvalued
2026-08-21P/E 23.0+42%Significantly overvalued ← now

Frequently asked questions

Is Johnson & Johnson stock overvalued?

At a blended P/E of 23.0 versus its historical normal P/E of 16.2, Johnson & Johnson trades about 42% above its typical valuation, with a PEG of 2.27 on 10.1% forward growth. tickerseer currently rates it significantly overvalued.

What is Johnson & Johnson's fair value and PEG?

Johnson & Johnson trades at a blended P/E of 23.0 against a historical normal P/E of 16.2, a PEG of 2.27, and a forward growth estimate of 10.1%.

Has tickerseer's rating of Johnson & Johnson changed?

tickerseer's rating moved from trading above fair value (2026-06-03) to significantly overvalued (2026-08-21).

What is the analyst price target for Johnson & Johnson?

The mean Wall Street price target for Johnson & Johnson is $272.50 across 22 analysts, 0.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track JNJ free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.